New trends in cholinergic therapy for Alzheimer disease: nicotinic agonists or cholinesterase inhibitors?
Giacobini
E
E
Department of Pharmacology, Southern Illinois University School of Medicine, Springfield 62794-1222, USA.
D000322:Adrenergic Agonists / Q000494:pharmacology; D018674:Adrenergic Antagonists / Q000494:pharmacology; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000502:physiology; D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008959:Models, Neurological; D018377:Neurotransmitter Agents / Q000378:metabolism; D018722:Nicotinic Agonists / Q000627:therapeutic use*
D000322:Adrenergic Agonists; D018674:Adrenergic Antagonists; D016229:Amyloid beta-Peptides; D002800:Cholinesterase Inhibitors; D018377:Neurotransmitter Agents; D018722:Nicotinic Agonists